CXCL8 and astrocytoma (excluding glioblastoma): Previous work using the selective antagonist NF340 [23] as well as a CRISPR/Cas9 knockout control had identified IL-6 and IL-8 as bona fide targets of the recombinant P2Y11 receptor in the astrocytoma 1321N1 cell line [19].